Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese Men

Wyeth is now a wholly owned subsidiary of Pfizer24 enrolled

Overview

The purpose of the study is to assess the safety and tolerability of ascending multiple oral doses of HCV-796 in healthy Japanese male subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

HCV-796DRUG

Eligibility

Sex: MALEMin age: 20 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ECG.

Locations (1)

Unnamed facility

Minato-ku, Tokyo, Japan

Outcomes

Primary Outcomes

Safety and pharmacokinetics

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.